Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Study Overview
=================
Brief Summary
-----------------
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Detailed Description
-----------------
Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.

Official Title
-----------------
Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Conditions
-----------------
Myocardial Infarction, Cerebral Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: available for 5 years of follow-up study Exclusion Criteria: Death caused other than cardiovascular and cerebralvascular diseases till the study ends Floating Population Pregnancy, lactation, or child bearing women Tumor Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L) Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| volunteer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with major adverse events | Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events. | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood routine, glucose and lipid profile; ECG; | the tests mentioned above will be taken once per year | 5 years | 
| serum adiponectin concentration, activity and isoforms | serum adiponectin concentration, activity and isoforms will be monitored once per year. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adiponectin, cardiovascular diseases, cerebrovascular diseases